Myasthenia Gravis Foundation of America (MGFA) Re-launches the MGFA Global MG Patient Registry with Partner Alira Health

Patients living with myasthenia gravis (MG) provide their health and symptom experience data in a safe, secure registry to drive new research and discoveries for improved disease understanding, better patient outcomes and treatments.

News
Published on:
January 25, 2023

BOSTON, MA – January 25, 2023 – The Myasthenia Gravis Foundation of America (MGFATM), the largest, leading patient advocacy organization solely dedicated to finding a cure for the rare neuromuscular disease myasthenia gravis (MG) while improving the lives of those living with MG, re-launched its MGFA Global MG Patient Registry. The registry enables patients diagnosed with MG to securely, safely submit their health and symptom data that will help researchers design and drive new research studies and clinical trials to improve disease understanding and patient outcomes and find better treatments for MG.

We see a future where patients are empowered to carry their own end-to-end health care information to obtain more effective treatments, better manage a disease, be healthier, or actively equip their circle of care to assist them. MGFA Global MG Patient Registry is an important step on this path. We are honored to partner with them to help improve the lives of patients with myasthenia gravis.”
Gabriele Brambilla CEO, Alira Health

The MGFA has partnered with Alira Health, a global healthcare firm whose mission is to humanize healthcare in partnership with patients, to develop and manage the registry while providing data analysis reporting. Alira Health has provided new, more efficient methods for patients to submit their data via a mobile phone application called Health StorylinesTM. The re-launch of the registry capitalizes on technological advances and better understanding of MG. Patients will add their data to the structured registry questionnaire twice a year, while also having the opportunity to contribute their day-to-day health experience data using the app, so that researchers can benefit from a deeper understanding of the lived experience of patients with MG.

“It is critical for researchers and clinicians to have access to real, up-to-date patient data to help design and build research studies and trials to more accurately prove out hypotheses and objectives,” said Samantha Masterson, president and chief executive officer of the MGFA. “Patients from around the world require data privacy, and now they can safely and securely share their data to help research sponsors make MG discoveries that could lead to better outcomes and treatments. Patient contributions to the registry will help drive new and better ways to treat MG.”

“We see a future where patients are empowered to carry their own end-to-end health care information to obtain more effective treatments, better manage a disease, be healthier, or actively equip their circle of care to assist them,” said Gabriele Brambilla, chief executive officer of Alira Health. “MGFA Global MG Patient Registry is an important step on this path. We are honored to partner with them to help improve the lives of patients with myasthenia gravis.”

This patient registry is a longitudinal, global, online repository of MG patient symptom and health data, shared directly by MG patients via online and mobile tools. It is safe, secure, and HIPPA-compliant, ensuring that patient data is protected and anonymized, so no one can directly attribute specific data points to members. The data is managed and maintained by the MGFA and its partner Alira Health to ensure data accuracy, hygiene, and quality.

Finding and enrolling sufficient numbers of patients in a short amount of time is a key challenge for research sponsors, especially in a rare disease space with a diverse set of manifestations. The registry data can supplement the trials so research professionals can move forward. Researchers, clinicians, and scientists will collaborate and invest with the MGFA to receive aggregated, anonymized yet detailed data reports that they can utilize to design studies, research scenarios, and run trials and research studies to help make new discoveries and test potential treatment pathways.

These research sponsors will be able to leverage longitudinal MG patient data to augment their trials and research studies, while testing new hypotheses and/or capturing long-term follow-up outcomes. Since the data is anonymized and aggregated, researchers will not have to solely rely on actual clinical trial applicants in order to run their research studies – enabling them to obtain final outcomes and results that could identify new treatments faster.

Data reporting will be communicated to the patient registry members so patients can see, in aggregate, the types of outcomes from the patient population. All published research will be communicated to the MG Community so they can read how the registry helps drive new discoveries.

MG patients can join the registry by using the following link to access and establish an account page.

About Alira Health

Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence. Alira Health’s integrated and multidisciplinary team of over 600 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.

About MGFA

The Myasthenia Gravis Foundation of America (MGFA) is the largest, leading patient advocacy organization solely dedicated to finding a cure and improved treatments for the rare neuromuscular disease myasthenia gravis (MG) by funding critical research discoveries and providing patient-centric programs, guidance, events, and webinars to connect, educate, and assist members of the global MG Community. You can visit the MGFA at myasthenia.org.

MGFA Contact Information:

Michael Antonellis
Vice President, Global Marketing & Communications
[email protected]
+1-617-610-2411

Kate Stober
National Director, Digital and Content Marketing
[email protected]
+1-480-744-2705

Alira Health Contact Information:

Susan Irving
Vice President of Global Marketing
[email protected]
+1-617-794-3478

Related news

News January 25, 2023
Myasthenia Gravis Foundation of America (MGFA) Re-launches the MGFA Global MG Patient Registry with Partner Alira Health
The registry enables patients diagnosed with MG to securely, safely submit their health and symptom data that will help researchers design and drive new research studies and clinical(...)
Clinical Trials Digital Health Patient Advocacy
News January 23, 2023
TerSera Therapeutics to sponsor “NET Cancer Health Storylines” by Alira Health and Carcinoid Cancer Foundation to support patients suffering from Carcinoid Syndrome Diarrhea
We are pleased to announce TerSera Therapeutics’ sponsorship with the Carcinoid Cancer Foundation (CCF) and Alira Health to expand and optimize a holistic patient journey digital(...)
Digital Health Digital Therapeutics Patient Centricity
News January 19, 2023
Alira Health Appoints Annabel de Maria Chief Patient Officer, Leading Global Patient Partnerships
Alira Health is pleased to announce today the appointment of Annabel de Maria as Chief Patient Officer. In this leadership capacity, she will spearhead the central role of patient engagement(...)
Patient Advocacy Patient Centric Patient Engagement
Publications January 19, 2023
What’s Next for Diabetes: Patient Engagement, Personalization, and Usable Technology
Alira Health partnered with the ADA to support this conversation and explore the most important topics emerging from patients, physicians, specialists, and patient advocates including(...)
Clinical Trials Diabetes MedTech Patient Engagement
Publications January 3, 2023
The Future of Healthcare: Patient-Owned Data
A revolution in patient data is upon us at long last...The future we envisioned then is now coming to fruition. This major paradigm shift puts data in the hands of patients, and we are ready for it.
Patient Advocacy Patient Centricity Patient Engagement
Publications December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Publications December 19, 2022
Alira Health’s Take on the EMA DCT Guidance
Last week the European Medicines Agency (EMA) published their “Recommendation Paper on Decentralised Elements in Clinical Trials”, providing guidance on new virtual methods in clinical(...)
Clinical Trials Decentralized Clinical Trials European Medicines Agency
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.